$MDCO (The Medicines Company)

$MDCO {{ '2016-05-09T15:42:28+0000' | timeago}} • Announcement

In addition to generating substantial non-dilutive cash, $MDCO expects the transaction and related restructuring to reduce the company's annual selling, general and administrative and related research and development expenses by between $65MM and $80MM.

$MLNT {{ '2018-01-08T17:08:01+0000' | timeago}} • Announcement

$MLNT completed the acquisition of $MDCO’s infectious disease business. $MLNT also announced that $MDCO’s Mike McGuire has joined the new organization as SVP, Commercial, replacing Chief Commercial Officer, John Temperato, who left $MLNT to pursue other opportunities.

$MDCO {{ '2018-01-08T13:17:52+0000' | timeago}} • Announcement

Pharma firm $MDCO closed the sale of its infectious disease business to $MLNT for $215MM of guaranteed cash and 3.3 MM common shares of Melinta. The sale consideration also includes royalty payments of 5-25% on certain drug sales and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products.

$MLNT {{ '2017-11-29T12:50:38+0000' | timeago}} • Announcement

Novel antibiotics developer $MLNT to acquire the infectious disease business of $MDCO. The purchase price also includes a payment by $MLNT to $MDCO of $25MM following each of the 12 and 18 month anniversaries of the closing date and payment to $MDCO of some royalty payments, based on tiered net sales of the acquired products in some jurisdictions.

$MLNT {{ '2017-11-29T12:49:30+0000' | timeago}} • Announcement

Novel antibiotics developer $MLNT to acquire the infectious disease business of $MDCO. The purchase price consists of a payment by $MLNT to $MDCO of $165MM in cash and issuance of shares equal to $50MM of Melinta stock, divided by 90% of volume weighted avg. price for the trailing 10 trading day period ending 3 trading days prior to closing.

$MLNT {{ '2017-11-29T12:47:52+0000' | timeago}} • Announcement

Novel antibiotics developer $MLNT to acquire the infectious disease business of $MDCO, which includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline). The acquisition is expected to close in 1Q18.

$MDCO {{ '2017-11-15T13:36:14+0000' | timeago}} • Announcement

$MDCO's BoD appointed current Chairman, Fredric Eshelman, to the newly created position of Executive Chairman, and Geno Germano, a pharmaceutical industry executive, as a new, independent Director. These appointments are effective immediately. Upon Eshelman's appointment as Executive Chairman, he resigned his position as Audit Committee member.

$MDCO {{ '2017-11-06T13:48:22+0000' | timeago}} • Announcement

$MDCO has initiated the phase-3 clinical program for inclisiran, a formulation for the treatment of atherosclerotic cardiovascular disease, in association with $ALNY. Patient dosing in the ORION-11 clinical trial began on November 1. The company expects data from the trials will support the submission of a New Drug Application by the end of 2019.

$MDCO {{ '2017-08-30T13:09:58+0000' | timeago}} • Announcement

$MDCO said the FDA has approved Vabomere (meropenem and vaborbactam) for injection for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.

$MDCO {{ '2017-08-28T12:09:36+0000' | timeago}} • Announcement

$MDCO and $ALNY announced positive data from the ORION-1 Phase II study of Inclisiran, an investigational, drug for the treatment of high cholesterol. The companies added that there were no deaths or serious adverse events during the extended observation period.

$MDCO {{ '2017-03-31T12:13:59+0000' | timeago}} • Announcement

$MDCO has appointed Paris Panayiotopoulos to its Board of Directors. Mr. Panayiotopoulos, who will serve as a Class I director, will stand for election at the company’s 2017 Annual Meeting of Stockholders.

$MDCO {{ '2017-02-28T12:55:08+0000' | timeago}} • Announcement

$MDCO's revenue for 4Q16 dropped to $25.2MM from $67.2MM last year. Included in revenue for 4Q16 was $9.1MM of royalty revenues derived from the gross profit on authorized generic sales of Angiomax (bivalirudin) by Sandoz, Inc. Worldwide Angiomax/Angiox (bivalirudin) net product sales fell to $7.8MM from $23.2MM.

$MDCO {{ '2017-02-28T12:54:45+0000' | timeago}} • Announcement

$MDCO reported a wider 4Q16 loss from continuing operations due to lower revenue. Loss from continuing operations widened to $124.43MM or $1.77 per share from $68.24MM or $0.99 per share last year. Adjusted loss per share widened to $1.19 from $0.86.

$MDCO {{ '2016-09-21T12:38:06+0000' | timeago}} • Announcement

$MDCO said the initial $32MM award will support a Phase IIIb trial of its investigational antibiotic, Carbavance, for treatment of gram-negative infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

$MDCO {{ '2016-09-21T12:37:05+0000' | timeago}} • Announcement

$MDCO said Biomedical Advanced Research and Development Authority (BARDA) will provide $32MM in initial funding, and up to an additional $100MM over about 5 years if all options to extend partnership are exercised by BARDA.

$MDCO {{ '2016-09-21T12:35:47+0000' | timeago}} • Announcement

$MDCO entered into a new strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA). The partnership was established under U.S. Department of Health and Human Services' (HHS) Other Transactional Authority (OTA) and is a distinctive, flexible, portfolio-based approach to funding drug development.

$MDCO {{ '2016-09-21T12:34:51+0000' | timeago}} • Announcement

$MDCO received up to $132MM to develop portfolio of new antibiotics targeting drug-resistant gram-negative infections under strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA).

$MDCO {{ '2016-08-31T15:14:41+0000' | timeago}} • Announcement

$MDCO said it provided an update on its clinical dyslipidemia research programs for MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor).

$MDCO {{ '2016-06-27T14:35:50+0000' | timeago}} • Announcement

$MDCO said it expects a reduction in annual selling, general and administrative and related research and development expenses of between $65MM and $80MM. After closing this deal, $MDCO will have executed two transactions with the potential to generate up to $1.2Bil in non-dilutive cash.

$MDCO {{ '2016-06-27T14:31:14+0000' | timeago}} • Announcement

$MDCO said it closed divestiture of its non-core cardiovascular assets, Cleviprex (clevidipine) injectable emulsion, Kengreal (cangrelor) and rights to Argatroban for Injection to Chiesi USA and its parent company Chiesi Farmaceutici. $MDCO received about $264MM in cash and has potential to receive up to $480MM in sales-based milestone payments.

$MDCO {{ '2016-06-15T16:33:20+0000' | timeago}} • Announcement

$MDCO said the Phase 2-3 development program for ABP-700 has been named VERONA by the company. The first Phase 2 study in the VERONA Program is expected to enroll 75 patients undergoing elective colonoscopies at three sites in The Netherlands. The study tests three ABP-700 infusion regimens with goal of enabling successful procedure completion.

Recent Transcripts

ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
TARO (Taro Pharmaceutical Industries Ltd.)
Wednesday, November 8 2017 - 1:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
CBM (Cambrex Corporation.)
Tuesday, November 7 2017 - 1:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
ACET (Aceto Corp.)
Friday, November 3 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, October 25 2017 - 12:30pm
LLY (Eli Lilly and Company)
Tuesday, October 24 2017 - 1:00pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ACET (Aceto Corp.)
Friday, August 25 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Wednesday, August 9 2017 - 8:30pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm

AlphaGraphics you may like